Bibliographic Details
| Title: |
Monoclonal Antibodies in Light of Mpox Outbreak: Current Research, Therapeutic Targets, and Animal Models. |
| Authors: |
Nikitin, Vladimir N.1 (AUTHOR), Merkuleva, Iuliia A.1 (AUTHOR) merkuleva_yua@vector.nsc.ru, Shcherbakov, Dmitriy N.1 (AUTHOR) |
| Source: |
Antibodies (2073-4468). Mar2025, Vol. 14 Issue 1, p20. 23p. |
| Subject Terms: |
*VIRUS diseases, *MONKEYPOX, *MONKEYPOX vaccines, *VIRAL proteins, *VACCINATION mandates |
| Abstract: |
The rapid rise in monkeypox virus infections among humans from 2022 to 2024 has captured the attention of the global healthcare community. In light of the lack of mandatory vaccination and limited data on next-generation vaccines for monkeypox prevention, the urgent development of therapeutic agents has become a priority. One promising approach involves the use of neutralizing monoclonal antibodies. This review highlights significant advancements in the search for antibodies against human pathogenic orthopoxviruses, particularly focusing on their potential application against the monkeypox virus. We also analyze viral proteins that serve as targets for identifying therapeutic antibodies capable of neutralizing a wide range of viruses. Finally, we deemed it essential to address the challenges associated with selecting an animal model that can adequately reflect the infectious process of each orthopoxvirus species in humans. [ABSTRACT FROM AUTHOR] |
|
Copyright of Antibodies (2073-4468) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
